Golden
venBio

venBio

A venture capital and private equity firm making early and late-stage investments in life science, healthcare, and therapeutics companies.

venBio is a venture capital and private equity firm early and late-stage investment in life science, healthcare, and therapeutics companies that is headquartered in San Francisco, California and was founded in 20011 by Corey Goodman, Kurt con Emter, and Robert Adelman.



Investments

As of November 2019 venBio has made 42 investments, has 20 companies in its portfolio, and has made 18 exits. Notable investments made by venBio include: Inbrace, Neurogastrix, Swfit Health Systems, Aeovian Pharmaceuticals, Checkmate Pharmaceuticals, Turning Point Therapeutics, Precision BioSciences, Akero Therapeutics, Oncobiologics, and Corvus Pharmaceuticals.



Investment funds

Fund II

On May 6, 2016 venBio announced raising $315 million for their second venture capital fund; exceeding its initial target of $250 million. The fund has three strategic limited parters which are Amgen, Merk, and Baxalta, and a group of financial limited partners. At the time of announcing their second fund venBio also announced adding Aaron Royston and Jaume Pons to their investment team. Robert Adelman, the managing partner of venBio, made the following statement regarding the firms second venture capital fund: 

We believe our fund model is unique. With the return of Amgen and Baxalta, along with the addition of Merck, the commitment from our Strategic Limited Partners is now larger than ever. Our investment model will remain the same. We continue to seek to finance promising life sciences companies that focus on therapeutics which we believe will make a difference for unmet medical needs.



Timeline

People

Name
Role
LinkedIn







Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References